Strategic IO Partnerships ImmunOs is actively pursuing combination strategies with checkpoint inhibitors, as evidenced by IOS-1002 in trials with Keytruda and past collaboration with Merck. This creates an immediate target list of pharma and biotech companies with PD-1/PD-L1, CTLA-4, CD47 and costimulatory programs for potential co-development, licensing, or strategic collaboration around iosH2 or IOS-1002.

Differentiated Platform Value The HLA-based immune modulation platform targeting LILRB receptors offers a first-in-class approach to remodel the tumor microenvironment and bolster existing immunotherapies. This unique mechanism can be positioned to partners as a complementary addition to established IO portfolios and as a basis for autoimmune applications, expanding collaboration opportunities.

Manufacturing Readiness Recent manufacturing activity with ProBioGen for IOS-1002 clinical materials indicates readiness to scale. This opens conversations for CDMO partnerships, tech transfer, and long-term supply arrangements to support expanded clinical programs and potential later-stage development.

Financing Signals A recent financing round signals investor appetite and potential for strategic partnerships. Leverage this posture to pursue co-development or licensing deals with pharma partners, outlining upfront milestones and value tied to program advancement and regulatory progress.

European Collaboration Potential Swiss headquarters with established US collaborations suggests strong cross-border collaboration potential. Target EU biotech and large-cap pharma seeking innovative IO combinations, proposing joint development, regional licensing, or co-commercialization pathways aligned with program milestones.